From Monkeys To Men: Panel Will Review Use Of Animal Rule For Filgrastim As Radiation Countermeasure
This article was originally published in The Pink Sheet Daily
FDA’s Medical Imaging Drugs and Oncologic Drugs Advisory Committee will discuss whether evidence supports approval of filgrastim as a medical countermeasure for radiation-induced bone marrow injury using the “animal rule.”
You may also be interested in...
Teva is the first company to get FDA approval of a version of Amgen’s Neupogen; one biosimilar expert questions why Teva did not switch its BLA to a biosimilar application when that pathway became available.
Study requirement for J&J’s antibiotic is less onerous than the studies that were imposed for the two other products approved under the Animal Rule.
Five-point plan that calls for FDA to change definition of ‘labeling’ and ‘substantial evidence’ may offer hints as to what the next iteration of 21st Century Cures legislation will offer.